



## Appendix 34 - NON-SMALL-CELL LUNG CARCINOMA (NSCLC)

### Approved settings/ treatment line

Protocols	Evidence level
<b>Neoadjuvant/ Adjuvant Sequential Chemotherapy</b>	
Cisplatin + Pemetrexed 4 Cycles.	Category 2A, Preferred, Non-Squamous
Cisplatin + Gemcitabine 4 cycles	Category 2A, Preferred, Squamous
Cisplatin + Docetaxel 4 cycles	Category 2A, Preferred, Squamous
Cisplatin + Vinorelbine 4 cycles	Category 2A, Squamous
Cisplatin + Etoposide 4 cycles	Category 2A, Squamous
Carboplatin + Paclitaxel 4 cycles*	Category 2A, Squamous
Carboplatin + Gemcitabine 4 cycles*	Category 2A, Squamous
Carboplatin + Pemetrexed 4 Cycles*	Category 2A, Non-Squamous
<b>Neoadjuvant/ Adjuvant Concurrent Chemo-radiotherapy</b>	
Cisplatin + Etoposide +RT	Category 2A, Preferred in squamous
Paclitaxel + Carboplatin + RT	Category 2A, Preferred
Cisplatin + Pemetrexed + RT	Category 2A, Preferred, Non-squamous
Carboplatin + Pemetrexed + RT	Category 2A, Preferred, Non-squamous
<b>EGFR Mutation +ve</b>	
Afatinib	Category 1
Osimertinib	Category 1, Preferred
Gefitinib	Category 1
Erlotinib	Category 1
Erlotinib + Ramucirumab	Category 2A
Erlotinib + Bevacizumab	Category 2B
<b>ALK, ROS-1 Rearrangement</b>	
Crizotinib	Category 1
Ceritinib	Category 1
Alectinib	Category 1, ALK-mutation only
<b>BRAF V600E Mutation +ve</b>	
Vemurafenib	Category 2A
<b>Advanced/ Metastatic Adenocarcinoma, Large cell types, No contraindications to PD-L1</b>	
Pembrolizumab/ Carboplatin/ Pemetrexed	Category 1, Preferred
Pembrolizumab/ Cisplatin/ Pemetrexed	Category 1, Preferred
Atezolizumab/ Carboplatin/ Paclitaxel/ Bevacizumab.	Category 1
Atezolizumab/ Carboplatin/ Nab-Paclitaxel	Category 2A
Nivolumab + Ipilimumab	Category 2A
<b>Advanced/ Metastatic Adenocarcinoma, Large cell types, contraindications to PD-L1</b>	
Carboplatin + Pemetrexed	Category 2A
Carboplatin + Paclitaxel	Category 1**#
Carboplatin+ Docetaxel	Category 1**#
Carboplatin + Gemcitabine	Category 1**#
Carboplatin + Etoposide	Category 1**#
Carboplatin + Nab-paclitaxel	Category 1**#
Bevacizumab/ Carboplatin/ Paclitaxel	Category 1**#
Bevacizumab/ Carboplatin/ Pemetrexed	Category 1**
Bevacizumab/ Cisplatin/ Pemetrexed	Category 1**
Cisplatin + Pemetrexed	Category 1**
Cisplatin + Paclitaxel	Category 1**
Cisplatin+ Docetaxel	Category 1**
Cisplatin + Gemcitabine	Category 1**



Protocols	Evidence level
<b>Advanced/ Metastatic Adenocarcinoma, Large cell types, contraindications to PD-L1 ( Continued)</b>	
Cisplatin + Etoposide	Category 1**
Gemcitabine + Docetaxel	Category 1**
Gemcitabine + Vinorelbine	Category 1**
Pemetrexed	Category 2A#
Paclitaxel	Category 2A#
Docetaxel	Category 2A#
Gemcitabine	Category 2A#
Gemcitabine/ Vinorelbine	Category 2A#
Gemcitabine/ Docetaxel	Category 2A#
Nab-paclitaxel	Category 2A#
<b>Advanced/ Metastatic Squamous cell, No contraindications to PD-L1</b>	
Pembrolizumab/ Carboplatin/ Paclitaxel	Category 1, Preferred
Pembrolizumab/ Carboplatin/ Nab-paclitaxel	Category 1, Preferred
Nivolumab + Ipilimumab	Category 2A
<b>Advanced/ Metastatic Squamous cell, contraindications to PD-L1</b>	
Carboplatin + Paclitaxel	Category 1**#
Carboplatin+ Docetaxel	Category 1**#
Carboplatin + Gemcitabine	Category 1**#
Carboplatin + Nab-paclitaxel	Category 1**#
Cisplatin + Paclitaxel	Category 1**
Cisplatin+ Docetaxel	Category 1**
Cisplatin + Gemcitabine	Category 1**
Cisplatin + Etoposide	Category 1**
Gemcitabine + Docetaxel	Category 1**#
Gemcitabine + Vinorelbine	Category 1**#
Carboplatin + Etoposide	Category 2A#
Paclitaxel	Category 2A#
Docetaxel	Category 2A#
Gemcitabine	Category 2A#
Nab-paclitaxel	Category 2A#
<p><i>*Protocols for patients who cannot tolerate cisplatin. **Considered as Category 1 if used in case of contraindication to PD-L1 Inhibitors with a performance status 0-1</i></p> <p><i># Considered as Category 2A if used in case of patients with performance status ≥ 2.</i></p>	